Aptevo Therapeutics (NASDAQ:APVO) Lowered to Sell Rating by Wall Street Zen

Aptevo Therapeutics (NASDAQ:APVO) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Separately, Weiss Ratings reiterated a “sell (e)” rating on shares of Aptevo Therapeutics in a research note on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold”.

Aptevo Therapeutics Stock Up 4.5%

Shares of APVO opened at $9.44 on Friday. The firm has a market cap of $8.87 million, a price-to-earnings ratio of -0.01 and a beta of 1.47. The company’s fifty day moving average is $18.03 and its 200-day moving average is $30.02. Aptevo Therapeutics has a 12 month low of $7.66 and a 12 month high of $1,807.20.

Aptevo Therapeutics (NASDAQ:APVO) last issued its quarterly earnings data on Thursday, November 6th. The biotechnology company reported ($40.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($37.62) by ($2.52). As a group, research analysts predict that Aptevo Therapeutics will post -15.84 earnings per share for the current fiscal year.

Institutional Trading of Aptevo Therapeutics

An institutional investor recently bought a new position in Aptevo Therapeutics stock. Virtu Financial LLC bought a new stake in Aptevo Therapeutics Inc. (NASDAQ:APVO) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 38,282 shares of the biotechnology company’s stock, valued at approximately $56,000. Virtu Financial LLC owned about 1.16% of Aptevo Therapeutics as of its most recent SEC filing. Institutional investors own 8.06% of the company’s stock.

About Aptevo Therapeutics

Aptevo Therapeutics, Inc is a clinical-stage biopharmaceutical company headquartered in Seattle, Washington, focused on the discovery and development of novel immunotherapies for oncology and autoimmune diseases. Founded in 2012 as a spin-off from Emergent BioSolutions, the company builds on expertise in protein engineering and translational research to create targeted biologics that engage the body’s immune system.

The company’s core technologies include the ADAPTIR platform, which enables the design of bispecific and multispecific protein scaffolds with customizable binding domains, and the KNOCKOUT platform, which incorporates non-natural amino acids to enhance therapeutic properties such as stability and half-life.